Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line

被引:63
作者
Lue, Shuqing [1 ]
Chen, Zhilong [2 ]
Yang, Jianmin [1 ]
Chen, Li [1 ]
Gong, Shenglan [1 ]
Zhou, Hong [1 ]
Guo, Lieping [1 ]
Wang, Jianmin [1 ]
机构
[1] Second Mil Med Univ, Changhai Hospital, Dept Hematol, Shanghai 200433, Peoples R China
[2] Donghua Univ, Inst Biol Sci & Technol, Dept Pharmaceut Sci & Technol, Shanghai, Peoples R China
关键词
D O I
10.1016/j.exphem.2008.04.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To study the mechanism of bortezomilb resistance in JurkatB lines derived from T-lymphoblastic lymphoma/leukemia Jurkat line. Materials and Methods. Cytotoxicities of popular chemotherapeutic drugs to JurkatB cells were analyzed by trypan blue assay. Functional drug efflux in JurkatB cells was determined by How cytometry utilizing daunorubicin and the expression of P-glycoprotein (P-gp) was detected by Western blot. mRNA expression levels of proteasome P5 subunit (PSMB5) were measured by quantitation real-time reverse transcription polymerase chain reaction. In situ hybridization was performed to detect the amplification of PSMB5 gene. The chymotrypsin-like activities were assayed by measuring the release of the fluorescent 7-amido-4-methyl-coumarin (AMC) from the substrate N-succinyl-Leu-Leu-Val-Tyr-AMC. Cytogenetic studies were performed using R-handed metaphases and fluorescence in situ hybridization (FISH) analysis. I kappa B-alpha levels were detected by Western blot. Results. No cross-resistance to daunorubicin, adriamycin, vindesine, and etoposide was found in JurkatB cells. No evidence of drug efflux was found in JurkatB cells and the expression of P-gp was negative. The PSMB5 mRNA was overexpressed in highly resistant JurkatB5 and JurkatB1 lines compared with parental Jurkat, corresponding well with the increase of chymotrypsin-like activity and a karyotype of i(14q). Amplification of PSMB5 gene was demonstrated by in situ hybridization and FISH. The decreased I kappa B-alpha level in JurkatB5 cells after bortezomib treatment indicating an upregulation of nuclear factor-kappa B (NF-kappa B) activity. Conclusion. The mechanism of bortezomib resistance is different from that of multidrug resistance. Overexpression of PSMB5 is an important mechanism for bortezomib resistance in JurkatB lines. NF-kappa B may play a critical role in evading the apoptotic effects. (C) 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.
引用
收藏
页码:1278 / 1284
页数:7
相关论文
共 33 条
[1]  
Adams J, 1999, CANCER RES, V59, P2615
[2]   Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts [J].
An, B ;
Goldfarb, RH ;
Siman, R ;
Dou, QP .
CELL DEATH AND DIFFERENTIATION, 1998, 5 (12) :1062-1075
[3]   Ubiquitin-mediated degradation of the proapoptotic active form of bid - A functional consequence on apoptosis induction [J].
Breitschopf, K ;
Zeiher, AM ;
Dimmeler, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (28) :21648-21652
[4]   Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells [J].
Chauhan, D ;
Li, GL ;
Podar, K ;
Hideshima, T ;
Mitsiades, C ;
Schlossman, R ;
Munshi, N ;
Richardson, P ;
Cotter, FE ;
Anderson, KC .
BLOOD, 2004, 104 (08) :2458-2466
[5]  
Chauhan D, 2003, CANCER RES, V63, P6174
[6]   Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly [J].
Chen, P ;
Hochstrasser, M .
CELL, 1996, 86 (06) :961-972
[7]   Proteasome inhibitors in the clinical setting: Benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors [J].
Cheriyath V. ;
Jacobs B.S. ;
Hussein M.A. .
Drugs in R & D, 2007, 8 (1) :1-12
[8]   Phase I study of bortezomib in refractory or relapsed acute leukemias [J].
Cortes, J ;
Thomas, D ;
Koller, C ;
Giles, F ;
Estey, E ;
Faderl, S ;
Garcia-Manero, G ;
McConkey, D ;
Patel, G ;
Guerciolini, R ;
Wright, J ;
Kantarjian, H .
CLINICAL CANCER RESEARCH, 2004, 10 (10) :3371-3376
[9]   Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation [J].
Craiu, A ;
Gaczynska, M ;
Akopian, T ;
Gramm, CF ;
Fenteany, G ;
Goldberg, AL ;
Rock, KL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (20) :13437-13445
[10]   Anti-angiogenic and anti-tumor properties of proteasome inhibitors [J].
Daniel, KG ;
Kuhn, DJ ;
Kazi, A ;
Dou, QP .
CURRENT CANCER DRUG TARGETS, 2005, 5 (07) :529-541